Vistagen Therapeutics Inc.
VTGN
Market Cap$119.99M
Close$
$1.98
55.3% downside
Current Fair Value
55.3% downsideOvervalued by 55.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $119.99 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 5.84 |
| Outstanding Shares | 27,025,209 |
| Avg 30 Day Volume | 164,139 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About VistaGen Therapeutics Inc
21 employeesVistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CN...